BioCentury
ARTICLE | Clinical News

Immunomedics reports Phase I/II metastatic breast cancer data for sacituzumab govitecan

May 18, 2018 2:11 PM UTC

Immunomedics Inc. (NASDAQ:IMMU) said sacituzumab govitecan (IMMU-132) led to an overall response rate (ORR) of 31% in a cohort of 54 patients with estrogen receptor-positive, HER2-negative metastatic breast cancer in the Phase I/II IMMU-132-01 trial. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

All responses were partial responses and all evaluable patients had received at least two prior treatments. In 37 patients who had received prior cyclin dependent kinase (CDK) inhibitors, the ORR was 24%...